Literature DB >> 17467934

Drug release study of large hollow nanoparticulate aggregates carrier particles for pulmonary delivery.

Kunn Hadinoto1, Kewu Zhu, Reginald B H Tan.   

Abstract

The aim of the present work is to examine the viability of using large hollow nanoparticulate aggregates as the therapeutic carrier particles in dry powder inhaler delivery of nanoparticulate drugs. The large hollow carrier particles are manufactured by spray drying of nanoparticulate suspensions of biocompatible acrylic polymer with loaded drugs. The size and concentration of the nanoparticles, as well as the phospholipids inclusion, have been known to influence the resulting morphology (i.e. size and degree of hollowness) of the spray-dried carrier particles. The effects of the resulting morphology of the carrier particles on the drug release rate are therefore investigated by varying the above three variables. The results of the drug release study are presented using aspirin and salbutamol sulfate as the model drugs with a varying degree of water solubility. The results indicate that the drug release rate is governed by the degree of hollowness of the carrier particles, and to a lesser extent by the nanoparticles size, as a result of the variation in the drug loading capacity of nanoparticles of different sizes.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17467934     DOI: 10.1016/j.ijpharm.2007.03.035

Source DB:  PubMed          Journal:  Int J Pharm        ISSN: 0378-5173            Impact factor:   5.875


  14 in total

1.  Inhalable microparticles as carriers for pulmonary delivery of thymopentin-loaded solid lipid nanoparticles.

Authors:  Yan-Zhen Li; Xun Sun; Tao Gong; Jie Liu; Jiao Zuo; Zhi-Rong Zhang
Journal:  Pharm Res       Date:  2010-07-13       Impact factor: 4.200

2.  Formation of protein nano-matrix particles with controlled surface architecture for respiratory drug delivery.

Authors:  Philip Chi Lip Kwok; Amolnat Tunsirikongkon; William Glover; Hak-Kim Chan
Journal:  Pharm Res       Date:  2010-12-07       Impact factor: 4.200

Review 3.  Pulmonary applications and toxicity of engineered nanoparticles.

Authors:  Jeffrey W Card; Darryl C Zeldin; James C Bonner; Earle R Nestmann
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2008-07-18       Impact factor: 5.464

Review 4.  Pulmonary delivery of nanoparticle chemotherapy for the treatment of lung cancers: challenges and opportunities.

Authors:  Sharad Mangal; Wei Gao; Tonglei Li; Qi Tony Zhou
Journal:  Acta Pharmacol Sin       Date:  2017-05-01       Impact factor: 6.150

Review 5.  Novel drug delivery systems targeting oxidative stress in chronic obstructive pulmonary disease: a review.

Authors:  You Xu; Hongmei Liu; Lei Song
Journal:  J Nanobiotechnology       Date:  2020-10-19       Impact factor: 10.435

Review 6.  Pharmacokinetics of inhaled nanotherapeutics for pulmonary delivery.

Authors:  Andrew M Shen; Tamara Minko
Journal:  J Control Release       Date:  2020-07-16       Impact factor: 9.776

7.  Formulation and pharmacokinetics of self-assembled rifampicin nanoparticle systems for pulmonary delivery.

Authors:  Jean C Sung; Danielle J Padilla; Lucila Garcia-Contreras; Jarod L Verberkmoes; David Durbin; Charles A Peloquin; Katharina J Elbert; Anthony J Hickey; David A Edwards
Journal:  Pharm Res       Date:  2009-04-30       Impact factor: 4.200

Review 8.  Nano-Therapeutics for the Lung: State-of-the-Art and Future Perspectives.

Authors:  Roshni Iyer; Connie C W Hsia; Kytai T Nguyen
Journal:  Curr Pharm Des       Date:  2015       Impact factor: 3.116

9.  Preparation of methotrexate-loaded, large, highly-porous PLLA microspheres by a high-voltage electrostatic antisolvent process.

Authors:  Ai-Zheng Chen; Yue-Mei Yang; Shi-Bin Wang; Guang-Ya Wang; Yuan-Gang Liu; Qing-Qing Sun
Journal:  J Mater Sci Mater Med       Date:  2013-05-10       Impact factor: 3.896

10.  Trojan microparticles for drug delivery.

Authors:  Nicolas Anton; Anshuman Jakhmola; Thierry F Vandamme
Journal:  Pharmaceutics       Date:  2012-01-06       Impact factor: 6.321

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.